Lung Adenocarcinoma Treatment Market, By Drug Class, By Therapy Type, By Stage of Treatment, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

Description

REPORT HIGHLIGHT

Lung Adenocarcinoma Treatment Market size was valued at USD 5,512.09 Million in 2023, expanding at a CAGR of 10.70% from 2024 to 2032.

The Lung Adenocarcinoma Treatment Market encompasses therapies specifically aimed at treating lung adenocarcinoma, a common subtype of non-small cell lung cancer. With rising global incidences, attributed to increased smoking rates and environmental factors, the market is witnessing significant growth. According to the American Cancer Society, approximately 236,000 new cases of lung cancer are expected in the U.S. in 2023, with adenocarcinoma accounting for nearly 40% of those cases. Advances in targeted therapies, such as epidermal growth factor receptor (EGFR) inhibitors and anaplastic lymphoma kinase (ALK) inhibitors, are enhancing treatment options, while immunotherapy is gaining traction for its effectiveness in advanced stages. However, challenges such as high treatment costs and adverse side effects may hinder market expansion. Nevertheless, ongoing research and development initiatives aimed at improving existing therapies and the emergence of personalized medicine present substantial opportunities for market players, fostering innovations that could transform patient outcomes in lung adenocarcinoma treatment.

Lung Adenocarcinoma Treatment Market- Market Dynamics

Rising Smoking Rates Fuel Growth in the Lung Adenocarcinoma Treatment Market

The escalating rates of smoking worldwide significantly contribute to the growth of the Lung Adenocarcinoma Treatment Market, as smoking is a primary risk factor for lung cancer. The World Health Organization (WHO) estimates that over 1.3 billion people are currently smokers, with tobacco use accounting for nearly 22% of cancer-related deaths globally. In the United States, the Centers for Disease Control and Prevention (CDC) reports that lung cancer is the leading cause of cancer mortality, with smoking responsible for approximately 85% of cases. As public awareness campaigns increase and smoking cessation programs are implemented, the demand for effective treatments is anticipated to rise. Pharmaceutical companies are responding to this trend by investing in innovative therapies, including targeted treatments and immunotherapies, to address the growing patient population. Additionally, initiatives from organizations like the American Lung Association aim to reduce smoking prevalence and improve early diagnosis, further driving the need for advanced treatment options in the lung adenocarcinoma sector.

Lung Adenocarcinoma Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 10.70% over the forecast period (2024-2032)

Based on Drug Class segmentation, EGFR Inhibitors were predicted to show maximum market share in the year 2023

Based on Therapy Type segmentation, Targeted Therapy was the leading type in 2023

Based on Stage of Treatment segmentation, Advanced or Metastatic Adenocarcinoma was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Lung Adenocarcinoma Treatment Market- Segmentation Analysis:

The Global Lung Adenocarcinoma Treatment Market is segmented on the basis of Drug Class, Therapy Type, Stage of Treatment, End-User, and Region.

The market is divided into four categories based on Drug Class: EGFR Inhibitors, ALK Inhibitors, PD-1/PD-L1 Inhibitors, and VEGF Inhibitors. EGFR Inhibitors hold the highest priority due to their effectiveness in targeting specific mutations. ALK Inhibitors follow, offering targeted therapy for ALK-positive patients, while PD-1/PD-L1 Inhibitors and VEGF Inhibitors provide additional treatment options.

The market is divided into four categories based on Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, and Combination Therapy. Targeted therapy ranks highest due to its precision in addressing specific cancer mutations. Immunotherapy follows, leveraging the immune system to combat cancer. Combination therapy is gaining traction, while chemotherapy remains a standard but less prioritized option.

Lung Adenocarcinoma Treatment Market- Geographical Insights

North America is a leading region in the Lung Adenocarcinoma Treatment Market, primarily due to high incidences of lung cancer and advanced healthcare infrastructure. According to the American Cancer Society, lung cancer is expected to account for about 25% of all cancer deaths in the U.S. in 2023. In 2022, the U.S. Food and Drug Administration (FDA) approved a new combination therapy of nivolumab and ipilimumab for patients with advanced lung adenocarcinoma, highlighting the ongoing innovation in treatment options. Europe follows closely, with countries like Germany and the UK increasing investment in lung cancer research and personalized medicine approaches. The European Society for Medical Oncology (ESMO) reports a growing emphasis on targeted therapies, supported by initiatives aimed at early detection and prevention. Meanwhile, Asia-Pacific is emerging as a significant market due to rising smoking rates and increasing healthcare expenditure, with collaborations between local firms and global pharmaceutical companies facilitating access to innovative treatments across the region.

Lung Adenocarcinoma Treatment Market- Competitive Landscape:

The competitive landscape of the Lung Adenocarcinoma Treatment Market is characterized by significant activities from key players in North America, which leads in market share due to advanced healthcare infrastructure and a high prevalence of lung cancer. In 2023, major pharmaceutical companies such as Roche and AstraZeneca announced collaborations to enhance the development of targeted therapies and immunotherapies. For instance, AstraZeneca's launch of its new drug, Tagrisso (osimertinib), has shown promise in treating patients with EGFR-mutated lung adenocarcinoma, making it a preferred choice among oncologists. Additionally, Bristol-Myers Squibb's acquisition of MyoKardia in late 2020 has enabled them to bolster their oncology portfolio, focusing on lung cancer therapies. European companies are also making strides, with a recent partnership between Novartis and the European Cancer Organization to improve patient access to innovative treatments. As competition intensifies, ongoing clinical trials and product innovations remain critical, shaping the future landscape of lung adenocarcinoma treatment options globally.

Recent Developments:

In April 2024, the FDA approved alectinib (Alecensa) as an adjuvant treatment for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) following tumor resection, with the condition confirmed by an FDA-approved test.

In March 2024, Pfizer Inc. announced the long-term follow-up results from the Phase 3 CROWN trial, which assessed the efficacy of LORBRENA (lorlatinib), a third-generation ALK inhibitor, against XALKORI (crizotinib) in patients with untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Amgen Inc.
Astellas Pharma Inc.
AstraZeneca PLC
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
Genentech, Inc. (Roche)
Gilead Sciences, Inc.
GlaxoSmithKline plc
Janssen Pharmaceuticals, Inc.
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited
Others

GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

EGFR Inhibitors
ALK Inhibitors
PD-1/PD-L1 Inhibitors
VEGF Inhibitors

GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032

Chemotherapy
Targeted Therapy
Immunotherapy
Combination Therapy

GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET, BY STAGE OF TREATMENT- MARKET ANALYSIS, 2019 - 2032

Early-Stage Adenocarcinoma
Advanced or Metastatic Adenocarcinoma

GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Oncology Clinics
Research Institutions

GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

Product Code: ANV4114

1. Lung Adenocarcinoma Treatment Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Lung Adenocarcinoma Treatment Market Snippet by Drug Class
- 2.1.2. Lung Adenocarcinoma Treatment Market Snippet by Therapy Type
- 2.1.3. Lung Adenocarcinoma Treatment Market Snippet by Stage of Treatment
- 2.1.4. Lung Adenocarcinoma Treatment Market Snippet by End-User
- 2.1.5. Lung Adenocarcinoma Treatment Market Snippet by Country
- 2.1.6. Lung Adenocarcinoma Treatment Market Snippet by Region
2.2. Competitive Insights

3. Lung Adenocarcinoma Treatment Key Market Trends

3.1. Lung Adenocarcinoma Treatment Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Lung Adenocarcinoma Treatment Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Lung Adenocarcinoma Treatment Market Opportunities
3.4. Lung Adenocarcinoma Treatment Market Future Trends

4. Lung Adenocarcinoma Treatment Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Lung Adenocarcinoma Treatment Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Lung Adenocarcinoma Treatment Market Landscape

6.1. Lung Adenocarcinoma Treatment Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Lung Adenocarcinoma Treatment Market - By Drug Class

7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
- 7.1.2. EGFR Inhibitors
- 7.1.3. ALK Inhibitors
- 7.1.4. PD-1/PD-L1 Inhibitors
- 7.1.5. VEGF Inhibitors

8. Lung Adenocarcinoma Treatment Market - By Therapy Type

8.1. Overview
- 8.1.1. Segment Share Analysis, By Therapy Type, 2023 & 2032 (%)
- 8.1.2. Chemotherapy
- 8.1.3. Targeted Therapy
- 8.1.4. Immunotherapy
- 8.1.5. Combination Therapy

9. Lung Adenocarcinoma Treatment Market - By Stage of Treatment

9.1. Overview
- 9.1.1. Segment Share Analysis, By Stage of Treatment, 2023 & 2032 (%)
- 9.1.2. Early-Stage Adenocarcinoma
- 9.1.3. Advanced or Metastatic Adenocarcinoma

10. Lung Adenocarcinoma Treatment Market - By End-User

10.1. Overview
- 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
- 10.1.2. Hospitals
- 10.1.3. Oncology Clinics
- 10.1.4. Research Institutions

11. Lung Adenocarcinoma Treatment Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Lung Adenocarcinoma Treatment Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Lung Adenocarcinoma Treatment Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.9. Italy
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.9.4. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.9.5. Italy Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.10. United Kingdom
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.10.4. United Kingdom Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.10.5. United Kingdom Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.11. France
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.11.4. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.11.5. France Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.12. Russia
  - 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.12.3. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Russia Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.13. Netherlands
  - 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.13.3. Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.13.4. Netherlands Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.15. Poland
  - 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.15.3. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Poland Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.16. Rest of Europe
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Rest of the Europe Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Lung Adenocarcinoma Treatment Key Manufacturers in Asia Pacific
- 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.4.5. Asia Pacific Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.4.6. Asia Pacific Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
- 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.8. India
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.8.4. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.8.5. India Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.9. China
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.9.4. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.9.5. China Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.13. Thailand
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Thailand Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.14. Indonesia
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Indonesia Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5. Latin America
- 11.5.1. Overview
- 11.5.2. Lung Adenocarcinoma Treatment Key Manufacturers in Latin America
- 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.5.5. Latin America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.5.6. Latin America Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
- 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa
- 11.6.1. Overview
- 11.6.2. Lung Adenocarcinoma Treatment Key Manufacturers in Middle East and Africa
- 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.6.5. Middle East and Africa Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.6.6. Middle East and Africa Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
- 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Lung Adenocarcinoma Treatment Industry

12.1. Competitive Dashboard
12.2. Company Profiles
- 12.2.1. Amgen Inc.
- 12.2.2. Astellas Pharma Inc.
- 12.2.3. AstraZeneca PLC
- 12.2.4. Bayer AG
- 12.2.5. Boehringer Ingelheim GmbH
- 12.2.6. Bristol-Myers Squibb Company
- 12.2.7. Eli Lilly and Company
- 12.2.8. Genentech, Inc. (Roche)
- 12.2.9. Gilead Sciences, Inc.
- 12.2.10. GlaxoSmithKline plc
- 12.2.11. Janssen Pharmaceuticals, Inc.
- 12.2.12. Merck & Co., Inc.
- 12.2.13. Novartis AG
- 12.2.14. Pfizer Inc.
- 12.2.15. Sanofi S.A.
- 12.2.16. Takeda Pharmaceutical Company Limited
- 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us